Results 171 to 180 of about 89,766 (303)

Comparison of chimeric mouse-human and humanized anti-CD25 monoclonal antibodies for steroid-refractory acute graft-versus-host disease. [PDF]

Front Immunol
Zheng X, Zhou Y, Zheng Y, Lu N, Cao Y, Zhai W, Wei J, Yang D, Zhang R, Pang A, Feng S, Han M, Jiang E, Chen X.   +13 more
europepmc   +1 more source

Considerations for the clinical use of teplizumab in stage 2 Type 1 diabetes: A Consensus Statement from the British Society of Paediatric Endocrinology and Diabetes (BSPED) and the Association of British Clinical Diabetologists (ABCD)

Diabetic Medicine, EarlyView.
Abstract Introduction In 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the use of teplizumab (a monoclonal anti‐CD3 antibody) to delay progression from Stage 2 to Stage 3 Type 1 diabetes in the UK. Methods To address the need for clear guidance on managing patients eligible for teplizumab therapy, the British Society of ...
Renuka P. Dias, M. Loredana Marcovecchio, Ruben H. Willemsen, Fiona Campbell, Ahmad Ashour, Philip Newland‐Jones, Jennifer Cooper, Parth Narendran, Neil P. Wright   +8 more
wiley   +1 more source

A novel bispecific antibody targeting OX40L and TNFα for the targeted treatment of rheumatoid arthritis. [PDF]

Antib Ther
Zhang Q, Song S.
europepmc   +1 more source

Structural Determination of a Human IgE Epitope on Major Birch Allergen Bet v 1

Allergy, EarlyView.
Andrea O'Malley, Brooke T. Borders, Jeffrey M. Wilson, Scott A. Smith, Maksymilian Chruszcz   +4 more
wiley   +1 more source

Islet Autoantibodies in Adult With Pituitary and Ovarian Autoimmunity: Implications for Type 1 Diabetes Screening

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Purpose Type 1 diabetes is a chronic autoimmune disease characterised by progressive pancreatic β‐cell destruction and the early appearance of islet autoantibodies (islet‐AAb) during the pre‐symptomatic phases. Given the growing interest in screening and prevention of type 1 diabetes, this study aimed to assess the prevalence of pancreatic ...
Giuseppe Bellastella, Michela di Nuzzo, Miriam Longo, Paolo Cirillo, Antonietta Maio, Nicole Di Martino, Silvia Angelino, Paola Caruso, Lorenzo Scappaticcio, Maria Teresa Vietri, Maria Ida Maiorino, Katherine Esposito   +11 more
wiley   +1 more source

Monoclonal antibodies for the therapy of cancer [PDF]

, 2014

core   +1 more source

Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives

European Journal of Haematology, EarlyView.
ABSTRACT Relapsed and refractory multiple myeloma (RRMM) remains associated with poor outcomes, particularly in patients exposed or refractory to proteasome inhibitors, immunomodulatory agents, and anti‐CD38 monoclonal antibodies. Targeting B‐cell maturation antigen (BCMA) has emerged as an effective therapeutic strategy, prompting the development of ...
Maria Eugenia Alvaro, Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Progress in the Treatment of Refractory Myasthenia Gravis. [PDF]

Rev Neurol
Liu D, Mao J, Song J, Wang M.
europepmc   +1 more source

Loncastuximab Tesirine in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: Evidence and Practical Guidance From Italian Clinical Experience

European Journal of Haematology, EarlyView.
ABSTRACT Patients with relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) who progress to the third‐line setting face a lack of standardized treatment, despite the presence of multiple available therapies. In this context, antibody–drug conjugates represent a relatively new class of anticancer agents; among them, loncastuximab tesirine is ...
Francesca Bonello, Andrea Aroldi, Alessia Castellino, Lara Mannelli, Elia Boccellato, Serena Rosati, Luisa Verga, Umberto Vitolo   +7 more
wiley   +1 more source

Novel assays to assess the prevalence and neutralizing potential of anti-IdeS antibodies in healthy humans. [PDF]

Front Immunol
Hannachi E, Trecco A, Daventure V, Delignat S, Bonilla P, Lecerf M, Thaunat O, Dimitrov JD, Deligne C, Lacroix-Desmazes S.   +9 more
europepmc   +1 more source